Natera falls after delaying study data for colorectal cancer test

Natera

09/08/2024 12:51

** Shares of Natera  NTRA.O  fall 1.9% to $105.68 premarket
    ** Late on Thursday, cancer test maker said it now expects
to rollout data from a study of its colorectal cancer test in Q1
2025 vs August this year
    ** However, co raised 2024 rev forecast to $1.49 bln to
$1.52 bln from $1.42 bln to $1.45 bln
    ** NTRA's Q2 rev of $413.4 mln beat Wall Street estimates of
$343 mln - LSEG 
    ** Co's Q2 loss of 30 cents/shr was narrower than estimates
of 69 cents/shr
    ** Up to last close, stock up 71.9% YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))